A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

This Phase III trial is testing whether adding an immunotherapy drug (adebrelimab) to standard chemoradiotherapy (combined chemotherapy and radiation) works better than chemoradiotherapy alone for locally advanced cervical cancer. The study focuses on patients with measurable tumors who have not had surgery. **You may be eligible if...** - You have locally advanced cervical cancer with at least one measurable lesion - You are in reasonably good health (ECOG 0 or 1) - You have adequate organ function (blood counts, liver, kidneys) - You are expected to survive at least 3 months **You may NOT be eligible if...** - Your cancer has spread to distant lymph nodes (above lumbar spine level L1) or to the groin area - You have received live vaccines within the past 4 weeks - You are on immune-suppressing medications - You have had prior immunotherapy for cervical cancer - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.